Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Agonist
55%
Bromodomain
54%
Proteolysis
52%
Methionine
51%
Epidermal Growth Factor Receptor
51%
BRD4
44%
Programmed Cell Death
43%
Tyrosine Phosphorylation
43%
Ruxolitinib
41%
NPM1
41%
Progenitor Cell
40%
Enhancer Region
40%
Messenger RNA
40%
RUNX1
38%
Cell Proliferation
36%
Oncogene C Myc
34%
Acetobacter
34%
Mutase
34%
Ribonucleotide
34%
Receptor Tyrosine Kinase
32%
Gene Expression
25%
CRISPR
24%
Protein Tertiary Structure
24%
Catenin
22%
Isoform
20%
LSD1
18%
ErbB
18%
Epigenetics
18%
Stem Cell
18%
Platelet
18%
GFI1
17%
Canine Model
17%
Very-Long-Chain Acyl-CoA Dehydrogenase
17%
Germline Mutation
17%
IRF4
17%
Copurification
17%
B Cell
17%
Epigenetic Mechanism
17%
Receptor Antagonist
17%
Peroxiredoxin 1
17%
Somatic Mutation
17%
Peptidomimetic
17%
SIRT2
17%
Translation (Protein Synthesis)
17%
RNA Sequencing
17%
JMJD6
17%
Cancer Cell
17%
Estrogen Receptor
17%
Progesterone Receptor
17%
Keyphrases
ErbB4
68%
Co-treatment
59%
AML Cells
57%
Myeloid Malignancies
51%
Preclinical Efficacy
51%
Overexpression
41%
Proteolysis Targeting chimera (PROTAC)
38%
EVI1
36%
Acute Myeloid Leukemia
34%
Menin Inhibitors
34%
MLL1
34%
Secondary Acute Myeloid Leukemia (sAML)
34%
Myeloproliferative Neoplasms
34%
Acute Myeloid Leukemia Cells
31%
ErbB2
28%
Venetoclax
27%
Neuregulin 2
25%
B-cell Lymphoma 2 (Bcl-2)
23%
Bromodomain
22%
Nucleophosmin 1 (NPM1)
22%
Human Breast Cancer
21%
ARV-825
21%
Clinical Outcomes
19%
Proteinase Inhibitor
19%
Lethal Activity
19%
Effective Therapy
19%
Oncoprotein
19%
C-Myc
18%
Tumor Suppressor
18%
Tumor
18%
Tumor Cell Lines
18%
FLT3 mutation
18%
Interdependency
18%
Improved Survival
17%
Patient-derived
17%
Lymphoma Cells
17%
Chimera
17%
Cellular Models
17%
Non-canonical Interactions
17%
Long-chain Fatty Acid Oxidation
17%
Interconversion
17%
Interactive Imaging
17%
Highly Active
17%
Acidophilic Bacteria
17%
3q26
17%
HER2 Extracellular Domain
17%
Epigenetic Mechanisms
17%
Dysregulation
17%
Richter Transformation
17%
Constitutively Active
17%
Pharmacology, Toxicology and Pharmaceutical Science
Bromodomain Inhibitor
69%
Secondary Acute Myeloid Leukemia
63%
Methionine
51%
Myeloproliferative Neoplasm
51%
Acute Myeloid Leukemia
36%
Protein Inhibitor
36%
Breast Cancer
34%
Venetoclax
33%
Neoplasm
30%
Tumor Suppressor Protein
28%
Neu Differentiation Factor
26%
Protein Tyrosine Kinase
26%
Transcription Factor
24%
Oncoprotein
23%
Tegavivint
23%
Catenin
22%
Lethality
20%
Ruxolitinib
18%
Malignant Neoplasm
17%
Diseases
17%
Zinc Finger Protein
17%
Peroxiredoxin 1
17%
Disease Exacerbation
17%
Oxidizing Agent
17%
Mantle Cell Lymphoma
17%
Peroxidase
17%
Wound Healing
17%
Partial Agonist
17%
Epidermal Growth Factor Receptor
13%
Reactive Oxygen Metabolite
13%
Messenger RNA
11%
Breast Tumor
11%
Wound
11%
Lymphoid Enhancer Factor 1
11%
Melanoma
11%
Drug Discovery
11%
Remission
10%
Birabresib
9%
MDS1 and EVI1 Complex Locus Protein
7%
Cytarabine
6%
Panobinostat
6%
Adavosertib
6%
Histone Deacetylase Inhibitor
6%
Ibrutinib
6%
Heat Shock Protein 90 Inhibitor
6%
Therapy Resistance
5%
Epidermal Growth Factor Receptor 4
5%
Clinical Study
5%
Metastatic Melanoma
5%
Volasertib
5%